Laurus Bio Secures $18.9M in Series B Funding to Drive the Future of Animal-Free Biomanufacturing

Laurus Bio, a proud subsidiary of Laurus Labs, is thrilled to announce that it has successfully raised $18,900,000 in new funding. As an integrated research-driven biomanufacturing organization with over 15 years of experience in precision fermentation and recombinant DNA technology, Laurus Bio has continuously pushed the boundaries of innovation across various industries. This significant capital infusion will fortify our commitment to developing and manufacturing ultra-pure, animal-origin-free recombinant proteins, growth factors, and cell-culture media supplements that are safe, virus-free, and sustainable. Our extensive expertise, built on a unique history in precision fermentation, enables us to cater to critical sectors such as stem cells and regenerative medicine, vaccines and biological drugs, cultured meat, and industrial-scale biotechnology for food, health, nutrition, and personal care. The new funding will drive advancements in our fermentation-based product development, streamline our strain engineering and clone development processes, and accelerate scale-up efforts to meet ever-growing market demands. Furthermore, it will enhance our capabilities as a Contract Development and Manufacturing Organization (CDMO), ensuring seamless support for novel protein companies and bio-manufacturers throughout every stage of the microbial precision fermentation value chain. At Laurus Bio, we believe that scientific progress and societal well-being go hand in hand; our corporate goals are deeply aligned with sustainable economic development and the pursuit of a healthier, safer future. This funding marks a pivotal moment for our organization, as we harness the power of synthetic biology to champion the global shift away from animal-derived products and towards a more sustainable, innovative biomanufacturing ecosystem.